Would you place your full trust in a healthcare provider that kept your medical records in spreadsheets or paper files? Not likely. But every day, one of our most valued business assets – biospecimen and related patient consent data – is placed into systems that are just as primitive.
In the era of “big data” and deep analysis, why do companies continue to manage this critical data in spreadsheets, rudimentary tracking tools and isolated laboratory information management systems (LIMS)?
When it comes to managing biospecimens and associated patient consent, there is a tendency to be short-sighted. The focus is on using "Band-Aids" to get through the current study, at the risk of lost productivity and increased regulatory risks. Without a systemic approach to track biosamples and consent across the entire ecosystem for both in-study and future-use purposes, we’re unable to focus on realizing more business value through more efficient studies and more usable samples.
The Business Costs of Poorly Managed Sample and Consent Data
Companies may have multiple sample-tracking systems, designed to meet the needs of different departments. But they’re seldom designed to communicate internally, let alone interface with third party systems. The current and future costs of maintaining separate solutions are enormous:
Current LIMS technologies are designed to manage lab data for a given facility, but they do not provide robust solutions for the management of end-to-end clinical trial samples and consent:
The track record for trying to force-fit LIMS into this ecosystem is poor, compared with purpose-built solutions.
The Future of Comprehensive Clinical Trial Sample Management is Here
Solutions are needed now to drive efficiency in complex trial execution and to fully realize investments in sample collection, tracking and storage. The dominance of precision medicine and genomics in clinical trials means that data once thought irrelevant may now be keys to a cure. We’re constantly discovering new ways to look at data. Regulatory requirements increasingly leave no room for error in biosample handling and use.
Samples are no longer a limited-use business asset, to be discarded or stored and forgotten after one use. There is immense clinical and business value in every sample, and we need to manage sample data just as we manage any business asset. We need to identify it, track it, store it consistently and electronically, and make it easy to analyze. In short, we need to move sample data up the value chain to deliver better clinical results.
With a comprehensive biospecimen and content management system, we can better execute today’s studies and streamline compliance, while maximizing the future value of each sample and potentially guiding the focus of future studies.
Imagine a world where you can move beyond today’s challenges and build a stronger foundation for future studies:
Like any business asset, biosample data needs to be managed by a secure, enterprise-grade system, with role-based access, compliance, standardization, redundancy, traceability, backup, and scalability. The system needs to enforce the relational integrity of data entities from multiple eClinical sources. Basic tracking tools and LIMS simply aren’t up to the job.
Where Do We Start?
We have to realize that the problems will never be solved with a short-sighted, ad hoc approach. Continued investment in isolated technology solutions without an enterprise view will simply compound the problem. The industry needs a purpose-built, enterprise-grade solution that leverages what’s in place and scales up for a rapidly growing and changing environment.
BioFortis – a Q2 Solutions Company - is the first technology company to support biospecimen tracking from a full lifecycle perspective in a distributed ecosystem of clinical trial sponsors, sites, labs, vendors, and biobanks.
The customers we are working with are already several years ahead of the industry, moving into a future of practical data management for biospecimen and consent data. It has been truly amazing to see the progress we have made together in such a short time and we see enormous potential to maximize the value of biosample data.
Recently expanded to nearly 165,000-square-feet, our state-of-the-art laboratory is equipped with a broad spectrum of enhanced scientific solutions for genomics, flow cytometry, translational science...
Speaker - Oswaldo A Lozoya, PhD, Genomics Staff Scientist - TSAIL, Q2 Solutions As part of the Machine Learning and Single Cell Genomics in Public Health session, Oswaldo presents insights,...
Biotech companies are powering the pharmaceutical pipeline by driving innovation to address unmet medical needs. Navigating a rapidly changing and increasing complex landscape takes expertise and...